Literature DB >> 35013853

Selective Spectrofluorimetric Protocol for Determination of Commonly Used Gram-negative Bactericidal Drug in Combined Pharmaceutical Dosage Forms and Human Plasma.

Tamer Z Attia1, Mahmoud A Abdelmajed2, Mahmoud A Omar3,4, Khalid M Badr El-Din3.   

Abstract

Gram-negative bacteria cause infections such as skin infection, meningitis, and pneumonia in human being. Gram-negative bacteria are highly resistant to most availaible bactericidal drugs. One of the most commonly used Gram-negative bactericidal drug is Polymyxin B sulfate (PMS). In addition, it is used in cases of highly resistant Gram-negative bacterial infections. The widespread of PMS necessitate the development of an exceedingly sensitive and selective fluorimetric assay for its determination in pure form, different pharmaceutical dosage forms, and human plasma. The presented method is used to determine PMS in their dosage form (vials) and combined pharmaceutical formulations (skin and eye ointments) with a high degree of accuracy and selectivity. The described procedure relies on the structure of a derivative of a high degree of fluorescence called dihydropyridine, via the condensation of the amino moiety of PMS with two equivalents of acetylacetone in the presence of formaldehyde and Teorell buffer (pH = 3). The fluorescent product was measured at 471 nm (λex = 402 nm). The linearity ranged from 100-3000 ng mL-1 of PMS with an excellent r2 of 0.9998. LOD and LOQ were 27.16 ng mL-1 and 82.30 ng mL-1, respectively. Owing to the developed method's high selectivity, it was successfully utilized for assay of PMS, in the ointment, in the presence of oxytetracycline as an active ingredient. Furthermore, the procedure applied for the estimation of parenteral PMS in human plasma with very good mean recovery 97.42 ± 1.46.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Fluorimetrically; Human plasma; Oxytetracycline; Polymyxin B Sulphate (PMS)

Mesh:

Substances:

Year:  2022        PMID: 35013853     DOI: 10.1007/s10895-021-02862-6

Source DB:  PubMed          Journal:  J Fluoresc        ISSN: 1053-0509            Impact factor:   2.217


  2 in total

1.  Validation of an UV spectrophotometric assay for the quantification of polymyxin B in solid lipid nanoparticles.

Authors:  P Severino; E F Silveira; M Vazzana; M V Chaud; M H A Santana; E B Souto
Journal:  Pharmazie       Date:  2015-11       Impact factor: 1.267

2.  Therapeutic drug monitoring of polymyxin B by LC-MS/MS in plasma and urine.

Authors:  Xiaofen Liu; Zhenwei Yu; Yu Wang; Hailan Wu; Xingchen Bian; Xin Li; Yaxin Fan; Beining Guo; Jing Zhang
Journal:  Bioanalysis       Date:  2020-06-19       Impact factor: 2.681

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.